Literature DB >> 11803471

A protective role for HIF-1 in response to redox manipulation and glucose deprivation: implications for tumorigenesis.

Kaye J Williams1, Brian A Telfer, Rachel E Airley, Hans P W Peters, Mary R Sheridan, Albert J van der Kogel, Adrian L Harris, Ian J Stratford.   

Abstract

We have investigated the role of HIF-1 in the cellular response to redox modulation via the inhibition of oxidative phosphorylation. We demonstrate that manipulation of redox in air, achieved by inhibiting cytochrome oxidase with cyanide, induces HIF-1 mediated transcription in wild-type CHO and HT1080 human tumour cells but not in CHO cells deficient in the oxygen responsive, HIF-1alpha sub-unit of HIF-1. Hypoglycaemia attenuates cyanide-mediated transcription in non-transformed HIF-1 wild-type CHO cells but not the human tumour derived cell line. Cells lacking either HIF-1alpha, or the second composite sub-unit of HIF-1, HIF-1beta, were markedly more sensitive to the combined stress of perturbed redox and hypoglycaemia than wild-type cells. As such conditions together with hypoxia are prevalent in tumours, these data suggest that HIF-1 may have a protective role in adaptation to the tumour micro-environment. In support of this we demonstrate that HIF-1alpha deficient cells are less tumorigenic than wild-type cells. They showed a reduced growth rate when grown as xenografts in nude mice. This was not related to vascular parameters that were identical to those found in HIF-1 wild-type tumours. The HIF-1 deficient tumours lacked focal expression of Glut-1 in hypoxic tumour regions. Compromised glucose uptake and metabolic adaptation to the tumour micro-environment may form the basis of the reduced tumorigenicity associated with these cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11803471     DOI: 10.1038/sj.onc.1205047

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  19 in total

1.  Clinicopathological significance and linkage of the distribution of HIF-1alpha and GLUT-1 in human primary colorectal cancer.

Authors:  Andrzej Wincewicz; Mariola Sulkowska; Mariusz Koda; Stanislaw Sulkowski
Journal:  Pathol Oncol Res       Date:  2007-03-27       Impact factor: 3.201

2.  Gene expression profiling of the hypoxia signaling pathway in hypoxia-inducible factor 1alpha null mouse embryonic fibroblasts.

Authors:  Ajith Vengellur; Barbara G Woods; Heather E Ryan; Randall S Johnson; John J LaPres
Journal:  Gene Expr       Date:  2003

3.  Overexpression of dimethylarginine dimethylaminohydrolase enhances tumor hypoxia: an insight into the relationship of hypoxia and angiogenesis in vivo.

Authors:  Vassiliki Kostourou; Helen Troy; Joanne F Murray; Elizabeth R Cullis; Guy St J Whitley; John R Griffiths; Simon P Robinson
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

4.  Relationships between hypoxia markers and the leptin system, estrogen receptors in human primary and metastatic breast cancer: effects of preoperative chemotherapy.

Authors:  Mariusz Koda; Luiza Kanczuga-Koda; Mariola Sulkowska; Eva Surmacz; Stanislaw Sulkowski
Journal:  BMC Cancer       Date:  2010-06-22       Impact factor: 4.430

5.  Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy.

Authors:  Bernard Burke; Athina Giannoudis; Kevin P Corke; Dalvir Gill; Michael Wells; Loems Ziegler-Heitbrock; Claire E Lewis
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

6.  Suppressing the malignant phenotypes of glioma cells by lentiviral delivery of small hairpin RNA targeting hypoxia-inducible factor-1α.

Authors:  Chang Gui Dong; William K K Wu; Su Yin Feng; Jun Yu; Jun Fei Shao; Gui Mei He
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

7.  Adaptation to HIF-1 deficiency by upregulation of the AMP/ATP ratio and phosphofructokinase activation in hepatomas.

Authors:  Monika Golinska; Helen Troy; Yuen-Li Chung; Paul M McSheehy; Manuel Mayr; Xiaoke Yin; Lucy Ly; Kaye J Williams; Rachel E Airley; Adrian L Harris; John Latigo; Meg Perumal; Eric O Aboagye; David Perrett; Marion Stubbs; John R Griffiths
Journal:  BMC Cancer       Date:  2011-05-25       Impact factor: 4.430

8.  Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells.

Authors:  D L Roberts; K J Williams; R L Cowen; M Barathova; A J Eustace; S Brittain-Dissont; M J Tilby; D G Pearson; C J Ottley; I J Stratford; C Dive
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

9.  Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance.

Authors:  Janine T Erler; Christopher J Cawthorne; Kaye J Williams; Marianne Koritzinsky; Bradley G Wouters; Clare Wilson; Crispin Miller; Costas Demonacos; Ian J Stratford; Caroline Dive
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

10.  Gene-expression profiling of microdissected breast cancer microvasculature identifies distinct tumor vascular subtypes.

Authors:  François Pepin; Nicholas Bertos; Julie Laferrière; Svetlana Sadekova; Margarita Souleimanova; Hong Zhao; Greg Finak; Sarkis Meterissian; Michael T Hallett; Morag Park
Journal:  Breast Cancer Res       Date:  2012-08-20       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.